Literature DB >> 14510637

Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms.

Marc Ouellet1, Jean-Pierre Falgueyret, M David Percival.   

Abstract

The sensitivity of Coxs (cyclo-oxygenases) to inhibition is known to be highly dependent on assay conditions. In the present study, the inhibitor sensitivities of purified Cox-1 and -2 were determined in a colorimetric assay using the reducing agent N, N, N ', N '-tetramethyl- p -phenylenediamine. With the detergent genapol X-100 (2 mM) present, the potencies of nimesulide, ibuprofen, flufenamic acid, niflumic acid and naproxen were increased over 100-fold against Cox-2 and titration curve shapes changed, so that maximal inhibition now approached 100%. Indomethacin, diclofenac and flosulide were not changed in potency. Similar effects of genapol were observed with inhibitors of Cox-1. DuP-697 and two analogues became more than 10-fold less potent against Cox-2 with genapol present. Tween-20, Triton X-100 and phosphatidylcholine, but not octylglucoside, gave qualitatively similar effects as genapol. Similar detergent-dependent changes in inhibitor potency were also observed using a [(14)C]arachidonic acid HPLC assay. The increases in potency of ibuprofen, flufenamic acid, isoxicam and niflumic acid towards Cox-2 and ibuprofen towards Cox-1 were accompanied by a change from time-independent to time-dependent inhibition. The interactions of Cox inhibitors has been described in terms of multiple binding step mechanisms. The genapol-dependent increase in inhibitor potency for ketoprofen was associated with an increase in the rate constant for the conversion of the initial enzyme-inhibitor complex to a second, more tightly bound form. The loss of potency for some inhibitors is probably due to inhibitor partitioning into detergent micelles. The present study identifies detergents as another factor that must be considered when determining inhibitor potencies against both Cox isoforms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14510637      PMCID: PMC1223887          DOI: 10.1042/BJ20030969

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  48 in total

Review 1.  Efficacy of cyclooxygenase-2-specific inhibitors.

Authors:  G W Cannon; F C Breedveld
Journal:  Am J Med       Date:  2001-02-19       Impact factor: 4.965

Review 2.  Cyclooxygenases: structural, cellular, and molecular biology.

Authors:  W L Smith; D L DeWitt; R M Garavito
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

3.  Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations.

Authors:  B S Selinsky; K Gupta; C T Sharkey; P J Loll
Journal:  Biochemistry       Date:  2001-05-01       Impact factor: 3.162

4.  Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity.

Authors:  C A Lanzo; J Sutin; S Rowlinson; J Talley; L J Marnett
Journal:  Biochemistry       Date:  2000-05-23       Impact factor: 3.162

5.  Purification and characterization of the human recombinant histidine-tagged prostaglandin endoperoxide H synthases-1 and -2.

Authors:  T Smith; J Leipprandt; D DeWitt
Journal:  Arch Biochem Biophys       Date:  2000-03-01       Impact factor: 4.013

6.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1.

Authors:  D Picot; P J Loll; R M Garavito
Journal:  Nature       Date:  1994-01-20       Impact factor: 49.962

7.  Reactive blue 2 is a potent inhibitor of a thylakoid protein kinase.

Authors:  S J Coughlan; J W Davenport; G Hind
Journal:  Eur J Biochem       Date:  1991-04-23

Review 8.  Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.

Authors:  F Buttgereit; G R Burmester; L S Simon
Journal:  Am J Med       Date:  2001-02-19       Impact factor: 4.965

9.  Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

Authors:  D Riendeau; M D Percival; C Brideau; S Charleson; D Dubé; D Ethier; J P Falgueyret; R W Friesen; R Gordon; G Greig; J Guay; J Mancini; M Ouellet; E Wong; L Xu; S Boyce; D Visco; Y Girard; P Prasit; R Zamboni; I W Rodger; M Gresser; A W Ford-Hutchinson; R N Young; C C Chan
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

10.  A study of human erythrocyte acetylcholinesterase inhibition by chlorpromazine.

Authors:  A Spinedi; L Pacini; C Limatola; P Luly; R N Farias
Journal:  Biochem J       Date:  1991-09-01       Impact factor: 3.857

View more
  7 in total

1.  Rational design of agonists for bitter taste receptor TAS2R14: from modeling to bench and back.

Authors:  Antonella Di Pizio; Lukas A W Waterloo; Regine Brox; Stefan Löber; Dorothee Weikert; Maik Behrens; Peter Gmeiner; Masha Y Niv
Journal:  Cell Mol Life Sci       Date:  2019-06-24       Impact factor: 9.261

Review 2.  Does the Preemptive Use of Oral Nonsteroidal Anti-inflammatory Drugs Reduce Postoperative Pain in Surgical Removal of Third Molars? A Meta-analysis of Randomized Clinical Trials.

Authors:  Fábio Wildson Gurgel Costa; Diego Felipe Silveira Esses; Paulo Goberlânio de Barros Silva; Francisco Samuel Rodrigues Carvalho; Carlos Diego Lopes Sá; Assis Filipe Medeiros Albuquerque; Tácio Pinheiro Bezerra; Thyciana Rodrigues Ribeiro; Cristiane Sá Roriz Fonteles; Eduardo Costa Studart Soares
Journal:  Anesth Prog       Date:  2015

3.  Inhibition of aminoacylase 3 protects rat brain cortex neuronal cells from the toxicity of 4-hydroxy-2-nonenal mercapturate and 4-hydroxy-2-nonenal.

Authors:  Kirill Tsirulnikov; Natalia Abuladze; Anatol Bragin; Kym Faull; Duilio Cascio; Robert Damoiseaux; Matthew J Schibler; Alexander Pushkin
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-20       Impact factor: 4.219

4.  Phospholipid actions on PGHS-1 and -2 cyclooxygenase kinetics.

Authors:  J Rand Doyen; Nur Yucer; Lenard M Lichtenberger; Richard J Kulmacz
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-12-08       Impact factor: 3.072

5.  Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs.

Authors:  Hongzhen Hu; Jinbin Tian; Yingmin Zhu; Chunbo Wang; Rui Xiao; Jeffrey M Herz; Jackie D Wood; Michael X Zhu
Journal:  Pflugers Arch       Date:  2009-11-04       Impact factor: 3.657

6.  Development of selective blockers for Ca²(+)-activated Cl channel using Xenopus laevis oocytes with an improved drug screening strategy.

Authors:  Soo-Jin Oh; Jung Hwan Park; Sungyu Han; Jae Kyun Lee; Eun Joo Roh; C Justin Lee
Journal:  Mol Brain       Date:  2008-10-29       Impact factor: 4.041

7.  Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.

Authors:  Kamila Anna Zub; Mirta Mittelstedt Leal de Sousa; Antonio Sarno; Animesh Sharma; Aida Demirovic; Shalini Rao; Clifford Young; Per Arne Aas; Ida Ericsson; Anders Sundan; Ole Nørregaard Jensen; Geir Slupphaug
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.